Navigation Links
Protein Thought to Promote Cancer Does Opposite
Date:7/12/2008

Study finds it functions as a tumor suppressor instead

FRIDAY, July 11 (HealthDay News) -- A protein that appears to suppress the growth of human cancer cells in lab cultures was, until recently, thought to promote colorectal cancer.

Previous animal studies have found that a gene called TCF7L2 is active in about 90 percent of colorectal cancers because of a biochemical malfunction in a gene. As a result, researchers suspected TCF7L2 triggered colorectal cancer in humans.

New technology used by University of Texas Southwestern Medical Center at Dallas researchers, however, allowed them to study the gene on human colorectal cancer cells. When the researchers switched off the TCF7L2 gene, human colorectal cancer cells actually grew stronger and more rapidly in lab cultures.

"This finding reshapes a fundamental model of how colorectal cancer arises," senior study author Lawrence Lum, an assistant professor of cell biology at UT Southwestern, said in a university news release.

The study was published online in this week's issue of the Proceedings of the National Academy of Sciences.

The next step, he said, is to understand more fully all the steps in the biochemical pathway involved in controlling the action of TCF7L2. This may help find new therapeutic targets for treating colorectal cancer.

More information

The American Cancer Society has more about colorectal cancer.



-- Kevin McKeever



SOURCE: University of Texas Southwestern Medical Center at Dallas, news release, July 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute
2. Discovery of key malaria proteins could mean sticky end for parasite
3. Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis
4. Protein thought to promote cancer instead functions as a tumor suppressor
5. Zinc finger proteins put personalized HIV therapy within reach
6. DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6(R) Cell Line Proteins
7. Gene silencer and quantum dots reduce protein production to a whisper
8. Could new discovery about a shape-shifting protein lead to a mighty morpheein bacteria fighter?
9. Alzheimers Protein Tied to HIV Progression
10. Is it time to revisit the current protein recommendations?
11. Lou Gehrigs protein found throughout brain, suggesting effects beyond motor neurons
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Protein Thought to Promote Cancer Does Opposite
(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg ... life. Although frozen embryos have a slight statistical advantage for live births, frozen ... a wonderful opportunity for women undergoing medical treatment or who are concerned about ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for ... 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device ... of The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... ... 21, 2017 , ... Innovatum will demonstrate capabilities of fully ... Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development addresses ... patient safety. , Microscan , a global technology leader in barcoding, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: